×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRK – merck & company, inc. (new) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
03:17 pm
mrk
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans [Yahoo! Finance]
Low
Report
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans [Yahoo! Finance]
12/19
02:39 pm
mrk
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Low
Report
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
12/19
10:04 am
mrk
Merck (MRK)'s CEO Has a “Better Hand,” Says Jim Cramer [Yahoo! Finance]
Low
Report
Merck (MRK)'s CEO Has a “Better Hand,” Says Jim Cramer [Yahoo! Finance]
12/18
10:49 pm
mrk
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case [Seeking Alpha]
Low
Report
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case [Seeking Alpha]
12/18
08:05 am
mrk
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $130.00 price target on the stock, up previously from $82.00.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $130.00 price target on the stock, up previously from $82.00.
12/17
07:26 am
mrk
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck's Keytruda [Seeking Alpha]
Low
Report
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck's Keytruda [Seeking Alpha]
12/17
07:10 am
mrk
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery [Yahoo! Fina
Low
Report
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery [Yahoo! Fina
12/17
06:45 am
mrk
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Low
Report
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
7/29/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-5.0%
merck & company, inc. (new)
4/24/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
0.8%
merck & company, inc. (new)
2/4/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-9.7%
merck & company, inc. (new)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
04:36 pm
mrk
Form 8-K Merck & Co., Inc. For: Dec 04
Low
Report
Form 8-K Merck & Co., Inc. For: Dec 04
12/2
06:03 am
mrk
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
Low
Report
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
11/12
04:12 pm
mrk
Form 13F-HR Merck & Co., Inc. For: Sep 30
Low
Report
Form 13F-HR Merck & Co., Inc. For: Sep 30
11/12
04:02 pm
mrk
Form 4 Merck & Co., Inc. For: Nov 10 Filed by: Downing Cristal N
Low
Report
Form 4 Merck & Co., Inc. For: Nov 10 Filed by: Downing Cristal N
11/10
04:08 pm
mrk
Form 144 Merck & Co., Inc. Filed by: Downing Cristal N
Medium
Report
Form 144 Merck & Co., Inc. Filed by: Downing Cristal N
11/5
04:10 pm
mrk
Form 10-Q Merck & Co., Inc. For: Sep 30
Low
Report
Form 10-Q Merck & Co., Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
TOP News Decliners
3/13
Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily]
-8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: